Search results for "HM"

showing 10 items of 10594 documents

Genetic Testing for Melanoma—Where Are We With Moderate-Penetrance Genes?

2016

International audience

0301 basic medicinePreimplantation genetic haplotypingSkin Neoplasmscdkn2aPenetranceDermatologypolicy statement update03 medical and health sciencesCDKN2ApredisposesmedicineHumansGenetic Predisposition to DiseaseGenetic Testingmitf germline mutationGeneMelanomaComputingMilieux_MISCELLANEOUSGenetic testingriskGeneticsmedicine.diagnostic_testbusiness.industryMelanomamedicine.diseaseMicrophthalmia-associated transcription factorcancer susceptibilityPenetrance030104 developmental biologyMutation (genetic algorithm)Mutationbusiness[ SDV.MHEP.DERM ] Life Sciences [q-bio]/Human health and pathology/Dermatologyamerican-society[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct

Familial Central Hypothyroidism Caused by a Novel IGSF1 Gene Mutation.

2016

Congenital hypothyroidism of central origin (CH-C) is a rare disease in which thyroid hormone deficiency is caused by insufficient thyrotropin stimulation of a normal thyroid gland. A recently described syndrome of isolated CH-C and macroorchidism was attributed to loss-of-function mutations of the immunoglobulin superfamily, member 1 gene (IGSF1).CH-C was diagnosed in three siblings. The TRH, TRHR, and TSHB genes were sequenced followed by whole-exome sequencing in the proband. A mutation identified in IGSF1 was analyzed by direct PCR sequencing in family members. The effects of the mutation were assessed by in vitro studies in HEK293 cells.The index case was negative for mutations in TRH,…

0301 basic medicineProbandMaleendocrine systemEndocrinology Diabetes and MetabolismDNA Mutational AnalysisImmunoglobulinsThyrotropin030209 endocrinology & metabolismBiology03 medical and health sciences0302 clinical medicineEndocrinologyHypothyroidismmedicineCentral hypothyroidismCongenital HypothyroidismHumansInsertionThyrotropin-Releasing HormoneGeneticsMacroorchidismReceptors Thyrotropin-Releasing HormoneSiblingsThyroidInfant NewbornInfantMembrane Proteinsmedicine.diseaseMolecular biologyCongenital hypothyroidismIGSF1030104 developmental biologymedicine.anatomical_structureHEK293 CellsChild PreschoolMutation (genetic algorithm)MutationThyroid : official journal of the American Thyroid Association
researchProduct

The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration

2016

The high-mobility group box 1 (HMGB1) protein has a central role in immunological antitumour defense. Here we show that natural killer cell-derived HMGB1 directly eliminates cancer cells by triggering metabolic cell death. HMGB1 allosterically inhibits the tetrameric pyruvate kinase isoform M2, thus blocking glucose-driven aerobic respiration. This results in a rapid metabolic shift forcing cells to rely solely on glycolysis for the maintenance of energy production. Cancer cells can acquire resistance to HMGB1 by increasing glycolysis using the dimeric form of PKM2, and employing glutaminolysis. Consistently, we observe an increase in the expression of a key enzyme of glutaminolysis, malic …

0301 basic medicineProgrammed cell deathThyroid HormonesCellular respirationScienceCell RespirationMalic enzymeGeneral Physics and Astronomychemical and pharmacologic phenomenaPKM2BiologyGeneral Biochemistry Genetics and Molecular BiologyArticle03 medical and health sciencesCell Line TumorHumansGlycolysisHMGB1 ProteinMultidisciplinaryGlutaminolysisCell DeathQMembrane ProteinsGeneral ChemistryCell biology030104 developmental biologyGlucoseCancer cellColonic NeoplasmsCarrier ProteinsGlycolysisPyruvate kinaseNature Communications
researchProduct

Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases

2015

ABSTRACT Leishmaniasis is one of the major neglected tropical diseases of the world. Druggable targets are the parasite cysteine proteases (CPs) of clan CA, family C1 (CAC1). In previous studies, we identified two peptidomimetic compounds, the aziridine-2,3-dicarboxylate compounds 13b and 13e, in a series of inhibitors of the cathepsin L (CL) subfamily of the papain clan CAC1. Both displayed antileishmanial activity in vitro while not showing cytotoxicity against host cells. In further investigations, the mode of action was characterized in Leishmania major . It was demonstrated that aziridines 13b and 13e mainly inhibited the parasitic cathepsin B (CB)-like CPC enzyme and, additionally, ma…

0301 basic medicineProteasesPeptidomimeticAziridines030106 microbiologyAntiprotozoal AgentsCysteine Proteinase InhibitorsCathepsin BLeishmania mexicanaCathepsin BCathepsin L03 medical and health sciencesTh2 CellsPapainPharmacology (medical)Leishmania majorAmastigoteLeishmaniasisLeishmania majorPharmacologybiologyChemistry; Biosynthesisbiology.organism_classificationLeishmania030104 developmental biologyInfectious DiseasesBiochemistrybiology.proteinAntimicrobial Agents and Chemotherapy
researchProduct

New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8

2018

Abstract In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some significant differences in the S2 pocket of LmCPB2.8 and cruzain, a related enzyme from Trypanosoma cruzi. Due to the presence of Tyr209 in LmCPB2.8 rather than Glu208 in cruzain sterically demanding, lipophilic ester groups (inhibitor 7d, 9d, 12d and 14d) are predicted to occupy the S2 pocket of the Leishmania protease, but do not…

0301 basic medicineProteasesStereochemistryCathepsin Lmedicine.medical_treatmentAziridinesLeishmania mexicana030106 microbiologyLeishmaniasis CutaneousCysteine Proteinase Inhibitors01 natural sciencesLeishmania mexicanaCathepsin L03 medical and health sciencesparasitic diseasesDrug DiscoverymedicineHumansLeishmaniasisLeishmaniaPharmacologyProteaseAntiparasitic Agentsbiology010405 organic chemistryChemistryOrganic ChemistryActive siteGeneral Medicinebiology.organism_classificationCysteine protease0104 chemical sciencesMolecular Docking SimulationDocking (molecular)biology.proteinCysteineEuropean Journal of Medicinal Chemistry
researchProduct

Parasites Dampen Dendritic Cell Activation to Ensure Their Survival

2017

Dendritic cells (DCs) are critical for induction of protective immunity against Leishmania major. However, DC activation occurs only several weeks after parasite transmission. Parasites synthesize a macrophage-inducible C-type lectin (Mincle) ligand. Engagement of Mincle by the parasite ligand dampens DC activation, thus delaying induction of interferon-γ-producing T cells responsible for parasite eradication.

0301 basic medicineProtective immunityLigandLectinmacromolecular substancesDendritic cellBiologybiology.organism_classificationCell biology03 medical and health sciences030104 developmental biologyInfectious Diseasesbiology.proteinParasite hostingParasitologyParasite transmissionLeishmania majorTrends in Parasitology
researchProduct

Asthmatics with high levels of serum surfactant protein D have more severe disease.

2016

Pulmonary surfactant is a mixture of lipids and surfactant-specific proteins that covers the alveolar surface, as well as the terminal conducting airways, lowering the surface tension at the air–liquid interface during breathing. The involvement of pulmonary surfactant in the pathophysiology of asthma has been suggested. An interesting working hypothesis is that the surface tension of the peripheral airways is altered in asthma, because the inflammatory process affects the structure and function of surfactant, leading to excessive airway narrowing and features of air trapping. We explored whether serum levels of surfactant protein D (SP-D) in asthmatics are related to the severity of the di…

0301 basic medicinePulmonary and Respiratory MedicineAdultMalesurfactantStatistics as TopicSevere diseasemacromolecular substancesSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineSeverity of illnessMedicineHumansAnti-Asthmatic Agentsbusiness.industrySmall airwaysSurfactant protein DReproducibility of Resultsrespiratory systemMiddle AgedPulmonary Surfactant-Associated Protein DAsthmaRespiratory Function Tests030104 developmental biology030228 respiratory systemImmunologyBiomarker (medicine)FemalebusinessBiomarkersThe European respiratory journal
researchProduct

The influence of microorganisms in allergic diseases.

2017

0301 basic medicinePulmonary and Respiratory MedicineImmunologyMEDLINEVirulenceT-Lymphocytes RegulatoryHelicobacter Infections03 medical and health sciences0302 clinical medicineTh2 CellsCytokines metabolismHygiene hypothesisHypersensitivityImmunology and AllergyMedicineAnimalsHumansChildAutoantibodiesAsthma therapyHelicobacter pyloriVirulencebusiness.industryProbioticsGeneral MedicineAsthmaBiological Therapy030104 developmental biologyHygiene HypothesisImmunologyCytokines030211 gastroenterology & hepatologybusinessIntroductory Journal ArticleAllergologia et immunopathologia
researchProduct

Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q

2020

Epidermal growth factor receptor (EGFR) L718Q is a rare resistant mutation which independently leads to third-generation tyrosine kinase inhibitor (TKI) resistance. Although a few studies have examined its resistance mechanisms, no effective treatment strategy has yet been proposed for patients with this mutation. Here, we report an effective treatment strategy for the rare EGFR L718Q mutation for the first time. A 44-year-old Chinese male patient initially presented with the sensitizing EGFR L858R mutation, and the progression-free survival (PFS) time after initial icotinib treatment was 9 months. When the progression of the disease (PD) and the EGFR T790M mutation were identified, he did …

0301 basic medicinePulmonary and Respiratory MedicineOncologyiMDT Cornermedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Tyrosine-kinase inhibitorTargeted therapy03 medical and health sciencesT790M0302 clinical medicineInternal medicinemedicineOsimertinibEpidermal growth factor receptorbiologybusiness.industrymedicine.disease030104 developmental biology030220 oncology & carcinogenesisMutation (genetic algorithm)Icotinibbiology.proteinbusiness
researchProduct

P1.13-16 The Diagnostic Accuracy of Circulating Tumor DNA for the Detection of EGFR-T790M Mutation in NSCLC: A Systematic Review and Meta-Analysis

2018

0301 basic medicinePulmonary and Respiratory Medicinebusiness.industryDiagnostic accuracyEGFR T790M03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCirculating tumor DNA030220 oncology & carcinogenesisMeta-analysisMutation (genetic algorithm)Cancer researchMedicinebusinessJournal of Thoracic Oncology
researchProduct